IMEXHS Secures A$1.4M Annual Revenue from New Colombian Radiology Deal
IMEXHS Limited has secured a significant one-year contract with Colombian cancer care provider Oncolife to deliver advanced radiology services, leveraging its integrated software and AI tools to enhance diagnostic precision.
- One-year contract with Oncolife for high-complexity oncology radiology
- Expected A$1.4 million in new annual recurring revenue
- Deployment of IMEXHS’s RIS/PACS platform and AI diagnostic layers
- Contract under new 2024 pricing model
- Strengthens IMEXHS’s position in Latin American healthcare markets
Strategic Expansion in Latin America
IMEXHS Limited (ASX, IME) has announced a material contract win with Oncolife, a prominent cancer-focused healthcare provider in Colombia. This agreement marks a key milestone for IMEXHS as it deepens its footprint in Latin America’s specialised healthcare sector, particularly in oncology diagnostics.
Oncolife operates a network of facilities including a main hospital in north Bogotá and centres in Villavicencio and Zipaquirá, all dedicated to cancer treatment. The contract calls for IMEXHS to provide high-complexity radiology services tailored to the needs of oncology patients, a segment that demands precision and advanced technology.
Integrated Technology and AI Support
Central to this partnership is the deployment of IMEXHS’s proprietary Radiology Information System (RIS) and Picture Archiving and Communications System (PACS), complemented by a patient portal and selected artificial intelligence diagnostic layers. These technologies are designed to streamline workflows, enhance diagnostic accuracy, and improve patient outcomes.
IMEXHS CEO Dr Germán Arango highlighted the synergy between their software solutions and radiology services, emphasizing how the new pricing model introduced in 2024 is delivering both growth and improved profitability. This contract is expected to generate approximately A$1.4 million in new annual recurring revenue, combining service fees and software licensing.
Implications for IMEXHS and the Market
This deal not only reinforces IMEXHS’s leadership in medical imaging services across 18 countries but also showcases the growing demand for specialised, technology-driven healthcare solutions in emerging markets. By focusing on high-value partnerships within oncology, IMEXHS is positioning itself to capture a larger share of the radiology services market in Latin America.
Investors will be watching closely to see how the integration of AI diagnostics influences operational efficiency and client satisfaction, as well as how this contract contributes to IMEXHS’s broader growth strategy.
Bottom Line?
IMEXHS’s Colombian contract signals a promising step in leveraging AI-driven radiology to expand its global healthcare impact.
Questions in the middle?
- Will the contract with Oncolife be extended beyond the initial one-year term?
- How will the AI diagnostic layers perform in real-world oncology settings?
- What impact will the new pricing model have on IMEXHS’s overall profitability?
